Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT02124486
Other study ID # RG_12-089
Secondary ID CS-011-02814/WM/
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date March 6, 2014
Est. completion date August 2, 2022

Study information

Verified date November 2020
Source University of Birmingham
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Idiopathic intracranial hypertension (IIH) is a condition with an unknown cause or causes. The condition is associated with raised pressure in the brain and can cause disabling daily headaches and loss of sight, which can be permanent. The raised brain pressure squashes the nerves supplying the eye (also known as papilloedema) and this can affect vision. Over 90% of patients with IIH are overweight and weight loss is the most effective treatment. Other treatments for IIH have very little current evidence to support their use. Weight loss is difficult to maintain. This trial aims to compare two methods of weight loss, bariatric surgery and the most effective dietary programme commonly available, Weight Watchers, to see which offers the most effective sustainable treatment for IIH. Bariatric surgery is recommended by the NICE clinical guidelines for patients with a Body Mass Index (BMI) of over 40, or over 35 with a co-morbidity. Women suffering from IIH have a BMI on average around 38 and IIH is not recognised as a co-morbidity for bariatric surgery. This trial will recruit 64 women with IIH from Neurology and Ophthalmology clinics in UK NHS Trusts. They will be randomised and 32 participants will be allocated to the dietetic intervention arm, and be enrolled in their local Weight Watchers group. 32 participants will be allocated to the bariatric surgery arm, and will be referred to their local bariatric surgery pathway to receive bariatric surgery. Both groups of participants will be allocated to a treatment arm which is proven to bring about weight loss. Participants will then be followed up for five years, with the most important measurement being their brain pressure after one year of being in the trial. A further 20 obese women who don't suffer from IIH will be recruited to compare the baseline symptoms and biomarkers of those with IIH; they will take no further part in the study. 5 further healthy individuals will be scanned twice in an MRI test group to validate the MRI scan sequence to be used in the trial.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 90
Est. completion date August 2, 2022
Est. primary completion date August 2, 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria: 1. Female IIH patients aged between 18 and 55 years, diagnosed according to the modified Dandy criteria who have chronic (> 6 months duration), active disease (papilloedema [Frisen grade = 1], significantly raised ICP > 25cmH2O) and no evidence of venous sinus thrombosis (magnetic resonance or CT imaging and venography as noted at diagnosis). 2. BMI >35kg/m2. 3. Tried other appropriate non-surgical treatments to lose weight but have not been able to achieve or maintain adequate, clinically beneficial weight loss for at least 6 months. 4. Able to give informed consent. Exclusion Criteria: 1. Age less than 18 or older than 55 years. 2. Pregnant or planning to conceive during the first 18 months of the trial . 3. Significant co-morbidity, endocrinopathy or the use of hormone manipulating medication (excluding contraception and topical or inhaled steroids). 4. Undergone optic nerve sheath fenestration. 5. Definite indication for or contraindication against surgery or dieting. 6. Have a specific medical or psychiatric contraindication for surgery, including drug misuse, eating disorder or major depression (suicidal ideation, drug overdose or psychological admission in last 12 months). 7. Previous bariatric surgery. 8. Taken AZD4017 within the last four months . 9. Inability to give informed consent e.g. due to cognitive impairment.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Bariatric surgery
Participants randomised to the bariatric surgery arm of the trial will be referred to the surgery pathway according to NICE guidelines at Birmingham Heartlands Hospital (BHH), Heart of England NHS Foundation Trust.
Behavioral:
Dietetic intervention
Participants randomised to the dietetic arm will be given vouchers at baseline, 3, 6 and 9 months that exempt them from paying for consecutive and specified weeks of their local Weight Watchers.

Locations

Country Name City State
United Kingdom University Hospital Birmingham (Queen Elizabeth Hospital) Birmingham West Midlands

Sponsors (2)

Lead Sponsor Collaborator
University of Birmingham National Institute for Health Research, United Kingdom

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Other Biomarkers Change in biomarkers from 0 to 12 (and 24 and 60) months 12 months
Other Matched control group comparison Comparison between IIH patients and the matched control group at baseline with respect to biomarkers and ICP. Baseline
Other MRI Test Run Change in MR imaging over a double baseline period of healthy controls. Baseline
Primary Intracranial Pressure Change in Intracranial Pressure (ICP) between baseline and 12 months.
ICP will be assessed using lumbar puncture (LP). To avoid the LP affecting the visual measures it will be performed after the visual tests have been completed. ICP will be recorded to the nearest whole number in cmH2O. Both opening and closing ICP will be recorded.
12 months
Secondary Intracranial Pressure Change in ICP between baseline and 24 and 60 months.
ICP will be assessed using lumbar puncture (LP). To avoid the LP affecting the visual measures it will be performed after the visual tests have been completed. ICP will be recorded to the nearest whole number in cmH2O. Both opening and closing ICP will be recorded.
60 months
Secondary IIH symptoms Change in reported IIH symptoms from 0 to 12 months (and at 3, 6, 24 and 60 months) 12 months
Secondary Visual function Change in visual function from 0 to 12 months (and at 24 and 60 months).
Assessments to be undertaken are the LogMAR (log of the minimum angle of resolution) chart to assess visual acuity, automated perimetry (Humphrey 24-2 central threshold) to measure the visual field mean deviation, an evaluation of contrast sensitivity and an Ishihara book to assess colour vision. The pupils will then be dilated using 1% tropicamide. Papilloedema will then be measured using spectral optical coherence tomography. Papilloedema will be further graded following fundus photographs. This will be done after all participants have reached the primary endpoint by two neuro-ophthalmologists blinded to trial treatment arm. The assessors will score the paired papilloedema images as better/same/worse as per the methodology described in a previous study. They will also assign a Frisen score to the images.
12 months
Secondary Papilloedema Change in papilloedema from 0 to 12 months (and at 24 and 60 months) 12 months
Secondary Headache Change in headache associated disability from 0 to 12 months (and at 24 and 60 months).
Headache will be assessed by participant completed questionnaires. Participants will complete a daily headache diary in the week before assessments, which will evaluate the Headache Index score and use of analgesia (days/week). Headache associated disability will be evaluated using the Headache Impact Test-6 score (HIT 6). Severity and frequency of headaches will be assessed retrospectively using the Headache Index. Headache phenotype (according to criteria from the International Headache Society) will also be assessed.
12 months
Secondary Anthropometric measures Change in anthropometric measures (e.g. waist, hip, fat mass) from 0 to 12 months (and at 24 and 60 months) 12 months
Secondary Quality of Life (EQ-5D-5L and SF-36) Change in quality of life (participant reported) from 0 to 12 months (and at 24 and 60 months) 12 months
Secondary Referrals to CSF shunting procedures and optic nerve sheath fenestration Difference in number of referrals to cerebrospinal fluid (CSF) shunting procedures and optic nerve sheath fenestration between treatment arms at 0 to 12 months (and at 24 and 60 months) 12 months
Secondary Health Economics Health economics including cost-effectiveness at 12, 24 and 60 months. 12 months
See also
  Status Clinical Trial Phase
Terminated NCT01863381 - Comparison of Continuous Non-Invasive and Invasive Intracranial Pressure Measurement N/A
Recruiting NCT06027567 - The Effect of an Anti-obesity Drug, Semaglutide, as Treatment in New-onset Idiopathic Intracranial Hypertension (IIH) Compared to Standard Weight Management (Dietician) With Regards to Change in Weight and Intracranial Pressure Phase 4
Active, not recruiting NCT02896452 - Astronaut Vision Issues in a Ground Analog Population: Polycystic Ovary Syndrome
Recruiting NCT06059703 - Biomarkers in the Etiology of Idiopathic Intracranial Hypertension N/A
Terminated NCT05347147 - A Trial to Determine the Efficacy and Safety of Presendin in IIH Phase 3
Not yet recruiting NCT06361823 - Exploratory Study on the Efficacy and Safety of Semaglutide for Idiopathic Intracranial Hypertension Treatment Phase 3
Recruiting NCT02143258 - Stenting of Venous Sinus Stenosis for Medically Refractory Idiopathic Intracranial Hypertension N/A
Enrolling by invitation NCT05308823 - Outcome of Cerebral Venous Sinuses Stenting on Idiopathic Intracranial Hypertension N/A
Not yet recruiting NCT05762367 - MR Lymphatic Imaging in Idiopathic Intracranial Hypertention N/A
Not yet recruiting NCT06436820 - ICP & Outflow Study
Completed NCT03867461 - The Effects of MAP and EtCO2 on Venous Sinus Pressures N/A
Completed NCT03963336 - Quantitative D-dimer Level and Anticoagulant Therapy in Idiopathic Intracranial Hypertension Early Phase 1
Completed NCT01003639 - Idiopathic Intracranial Hypertension Treatment Trial Phase 2/Phase 3
Recruiting NCT03096743 - Evaluating Raised Intracranial Pressure Using MR Elastography N/A
Completed NCT04314128 - Assessment of ICP in Idiopathic Intracranial Hypertension Using Transocular Ultrasound and Transcranial Doppler N/A
Terminated NCT03501966 - Surgical Idiopathic Intracranial Hypertension Treatment Trial Phase 3
Active, not recruiting NCT03556085 - Venous Sinus Stenting With the River Stent in IIH N/A
Completed NCT02017444 - Safety and Effectiveness of 11b-Hydroxysteroid Dehydrogenase Type 1 Inhibitor (AZD4017) to Treat Idiopathic Intracranial Hypertension. Phase 2